SANA.US Sana Biotechnology Inc

Healthcare Biotechnology USA Stocks
1.88 USD
Close of Nov 18, 2026
1.84 5.49
Market cap
USD 563M
P/E
-
P/B
3.11x
ROE
-66.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SANA.US undervalued?

Graham number

The Graham number of Sana Biotechnology Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sana Biotechnology Inc fundamental analysis

No fundamental analysis for Sana Biotechnology Inc yet.

Sana Biotechnology Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes…

Full company profile